Yme Alkema
Keine laufenden Positionen mehr
Profil
Yme Alkema joined Atugen in October 2005 and serves as Director of Business Development.
Prior to joining Atugen, he was Director of Business Development for Specs B.V, Kiadis B.V./ Screentec B.V, and Biofrontera AG.
Mr. Alkema has 25 years of international commercial experience, thereof 15 years in the biotech industry.
He received a BA degree in Commercial Economics from the HEAO (school for higher economic studies).
Ehemalige bekannte Positionen von Yme Alkema
| Unternehmen | Position | Ende |
|---|---|---|
Kiadis BV
 Kiadis BV Pharmaceuticals: MajorHealth Technology Kiadis BV is a drug discovery and development company with a focus on oncology and metabolic disorders. Kiadis has developed a proprietary technology platform, BioSelact technology that is used to perform drug discovery screening programs using natural extracts as well as synthetic mixtures and with the key advantage of direct identification and dereplication of the active compounds present in extracts or mixtures. The company is headquartered in Groningen, the Netherlands. | Corporate Officer/Principal | - |
| BIOFRONTERA AG | Corporate Officer/Principal | - |
Atugen AG
 Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOFRONTERA AG | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Kiadis BV
Kiadis BV Pharmaceuticals: MajorHealth Technology Kiadis BV is a drug discovery and development company with a focus on oncology and metabolic disorders. Kiadis has developed a proprietary technology platform, BioSelact technology that is used to perform drug discovery screening programs using natural extracts as well as synthetic mixtures and with the key advantage of direct identification and dereplication of the active compounds present in extracts or mixtures. The company is headquartered in Groningen, the Netherlands. | Health Technology |
Atugen AG
Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Health Technology |
